Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has ... and Regeneron's Dupixent (dupilumab) in AD.
Dupixent is already a massive seller, with turnover of $12 billion last year from its current use in other diseases like atopic dermatitis and severe asthma, and COPD could help drive it to $20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback